No Data
Shandong Jincheng Pharmaceutical Group's Antibiotic Gets Chinese Drug Regulator's Approval
Express News | Shandong Jincheng Pharmaceutical Group: Subsidiary Jincheng Suhui obtained the registration certificate for cefoxitin and sulbactam dry suspension pharmaceutical.
shandong jincheng pharmaceutical group (300233.SZ): Cefamandole nafate dry suspension passed consistency evaluation
shandong jincheng pharmaceutical group (300233.SZ) announced that its wholly-owned subsidiary shanghai jinchengsuzhi pharmaceutical co., ltd. (referred to as ...
Jincheng Pharmaceutical: Report for the third quarter of 2024
shandong jincheng pharmaceutical group (300233.SZ) released its performance for the first three quarters, with a net income of 0.151 billion yuan, an increase of 14.02%.
shandong jincheng pharmaceutical group (300233.SZ) released the third quarter report of 2024, the company's revenue in the first three quarters was 2...
Shandong Jincheng Pharmaceutical Group (300233.SZ): signed a framework agreement with China Pharmaceutical University to jointly establish the "Women's Health Drug Innovation Center".
格隆汇September 27th | Shandong Jincheng Pharmaceutical Group (300233.SZ) announced that the company recently signed a "Framework Agreement on Co-building the 'Women's Health Drug Innovation Center'" with China Pharmaceutical University. Based on the principles of "complementary advantages, synergistic innovation, and common development", leveraging Shandong Jincheng Pharmaceutical Group's advanced modern production technology and brand advantages in women's health products, as well as the talent advantages and product development research technology foundation of China Pharmaceutical University, integrating the advantages of school-enterprise select resources industries index, focusing on women's health, and conducting drug research and innovation. Following the principles of "platform co-construction, resource sharing, project co-management, and innovative breakthroughs" between the two parties, using project cooperation as a carrier.
No Data
No Data